Skip to Content

Research & Funding

Past Other NCI & NIH InitiativesRSS

This page lists past other NCI and NIH cancer imaging initiatives, including grant mechanisms.

Requests for Application (RFA) are usually announced with special application dates; there is no possibility for applying after that date. Program Announcements (PA, PAR) may be open for a set period of time, such as 3 years or less; applications submitted in response to Program Announcements may be due on the standard dates (February 1, June1, and October 1) or may have special dates for receipt of applications. Please pay attention to these dates. Contact a CIP staff member if you have questions.

  • PAR-06-459: Bioengineering Research Partnerships (BRP) [R01]

    • Release Date: June 26, 2006
    • Application Receipt Date: N/A
    • Expiration Date: N/A

    The primary objective of this program announcement is to encourage basic, applied, and translational bioengineering research that could make a significant contribution to improving human health. Bioengineering integrates physical, engineering, and computational science principles for the study of biology, medicine, behavior, or health. It advances fundamental concepts, creates knowledge from the molecular to the organ systems level, and develops innovative biologicals, materials, processes, implants, devices, and informatics approaches for the prevention, diagnosis, and treatment of disease, for patient rehabilitation, and for improving health. Some BRP projects may propose research that could lead to a novel device as a product. Partnership with companies that have relevant expertise or that may eventually be involved in commercialization is appropriate under the BRP program.

    A second objective is to encourage collaborations and partnerships among the allied quantitative and biomedical disciplines. A BRP must bring together the necessary physical, engineering, and computational science expertise with biological or clinical expertise and resources to address a significant area of bioengineering research within the mission of the NIH. In addition to the benefits to be derived from the research, the collaborations and partnerships can create opportunities for trans-disciplinary communication and training for a new generation of scientists capable of interacting across traditional technical boundaries.

    Applications for a BRP award should focus bioengineering research on an area of basic, applied, translational, behavioral, or clinical research that supports the missions of the participating NIH institutes and centers and where progress is likely to make a significant contribution to improving human health. Some NIH institutes and centers have indicated that they will only consider BRP applications in specific focus areas or use different budget caps. These institutes and focus areas are available at

    See full description in NIH Guide:PAR-06-459

  • PAR-06-455: The NCI Transition Career Development Award (K22)

    • Release Date: June 16, 2006
    • Application Receipt Date: Standard dates apply
    • Expiration Date: July 2, 2009
    • Contacts:

      Dr. David J. Eckstein, NCI, Phone: 301-496-8580, Email:

    The major objective of the NCI Transition Career Development Award program is two-fold: (i) to provide a mechanism for stabilizing the career tracks of the most promising of investigators while they are establishing their first independent research programs and (ii) to create equal access to extramural career development opportunities to postdoctoral scientists in basic human cancer research working as Federal employees.

    See full description in NIH Guide:PAR-06-455

  • PA-06-468: Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants (T32)

    The objective of the NRSA program is to provide predoctoral and postdoctoral research training opportunities for individuals interested in pursuing research careers in biomedical, behavioral and clinical research. Each NIH Institute and Center has a unique scientific purview and different program goals and initiatives that evolve over time. It is therefore critical that all applicants consult with the scientific/research contact at the relevant NIH Institute or Center for current information about program priorities and policies before preparing an application. This action is of utmost importance because applications with marginal or no relevance to the NIH awarding components participating in this funding opportunity announcement will not be accepted for review or considered for funding.

    See full description in NIH Guide:PA-06-468

  • PAR-06-451: Quick-Trials for Novel Cancer Therapies: Exploratory Grants (R21)

    • Release Date: June 09, 2006
    • Application Receipt Date: August 9, 2006; December 9, 2006; April 9, 2007; July 9, 2007; November 9, 2007
    • Expiration Date: December 10, 2007 (unless reissued) Reissued as PAR-08-025 New Expiration Date: Nov 10, 2010
    • Contacts:

      Dr. Roy Wu, NCI, Phone: 301-496-8866, Email:

    This FOA is aimed at providing a new approach in the grant application process by offering a rapid turnaround from application submission to funding. Features of this initiative include a modular grant application and award process, inclusion of the clinical protocol within the grant application, and an accelerated peer review with the goal of issuing new awards within 6 months of application receipt. Inclusion of the complete clinical protocol within the grant application is intended to simplify the application process by eliminating the need to duplicate protocol details in the Research Plan section and to insure proper peer review of the application. In addition, QUICK-TRIAL applications do not require extensive preliminary data in the grant application and support exploratory translational and clinical research studies involving cancer prevention, chemotherapy, and rapid development and application of novel clinical cancer therapies, including image-guided therapeutic procedures.

    See full description in NIH Guide:PAR-06-451

    Reissue Announcment:PAR-08-025

  • PAR-06-411: Exploratory Innovations in Biomedical Computational Science and Technology (R21)

    • Application Receipt/Submission Date(s): June 24, 2006; September 24, 2006; January 24, 2007; May 24, 2007; September 24, 2007; January 24, 2008; May 24, 2008; September 24, 2008, January 24, 2009

    The NIH is interested in promoting research and developments in computational science and technology that will support rapid progress in areas of scientific opportunity in biomedical research. As defined here, biomedical computing or biomedical information science and technology includes database design, graphical interfaces, querying approaches, data retrieval, data visualization and manipulation, data integration through the development of integrated analytical tools, and tools for electronic collaboration, as well as computational and mathematical research including the development of structural, functional, integrative, and analytical models and simulations.

    See full description in NIH Guide:PAR-06-411

  • Interdisciplinary Research Consortium (U54) Preapplication for Interdisciplinary Research Consortium (X02)

    • Release Date: April 10, 2006
    • Application Receipt Date: N/A
    • Expiration Date: N/A

    Dates: LOI: March 21, 2006; Pre-application: April 18, 2006 - Use SF-424 Electronic Submission.

    The Interdisciplinary Research Implementation Group will invite applications for Interdisciplinary Research Consortia from among those that submit a pre-application in response to PAR-06-122. This RFA with Limited Eligibility for a full consortium is released early to aid those who are writing a pre-application. Only those selected through a peer review of their pre-application are eligible to apply for a full Interdisciplinary Research Consortium. The purpose of this program is to support interdisciplinary approaches to solving significant and complex biomedical problems, particularly those that have been resistant to traditional approaches. These applications must hold the promise of leading to new research approaches to improving human health. Interdisciplinary consortia are expected to identify an important biomedically relevant problem, evaluate why previous approaches have not worked, justify why the proposed interdisciplinary approach will work, identify the methods that will keep the interdisciplinary team focused and coordinated, and propose a timeline. The review criteria will involve both the significance of the problem as well as the interdisciplinary nature of the approach to solving the problem. Applications will have to be strong in both of these areas. A successful interdisciplinary approach is defined as combining aspects of individual disciplines to provide a new conceptual approach to solving a problem that is likely to yield insights that could not have been achieved by an isolated laboratory or using a multi-disciplinary approach.

    Consortium RFA

  • RFA-CA-06-014: Tumor Microenvironment Network (TMEN) (U54)

    • Release Date: April 10, 2006
    • Application Receipt Date: May 10, 2006
    • Expiration Date: N/A

    Letter of Intent Receipt Date: April 10, 2006
    The NCI invites cooperative agreement and NIH intramural applications from groups of investigators interested in becoming components of the NCI Tumor Microenvironment Network (TMEN). The main objective is to delineate mechanisms of tumor-stroma interactions in human cancer and to generate a comprehensive understanding of composition of the stroma in normal tissues as well as its roles in tumor initiation, progression, and metastasis.

    See full description in NIH Guide:RFA-CA-06-014

  • RFA-RM-06-007: Nanomedicine Development Centers (PN2)

    • Release Date: April 10, 2006
    • Application Receipt Date: June 23, 2006
    • Expiration Date: N/A

    Concept Approval Letter Receipt Date: March 15, 2006
    Nanomedicine is one of nine major initiatives included in the NIH Roadmap. Because Nanomedicine is an emerging biomedical discipline, the NIH engaged the biomedical research community to help define and develop concepts and a framework to stimulate work in this field. A two-year planning process, (see culminated in the establishment of a collaborative national network of Nanomedicine Development Centers (NDC). The first four centers were awarded in fiscal year 2005. The current RFA solicits applications for additional centers that will expand the network by addressing complementary models, topics, medical targets, and approaches to the work of funded centers.

    See full description in NIH Guide: RFA-RM-06-007

    Concept Approval Letter Evaluation Information

  • PA-06-149: Innovative and Exploratory Research in Digestive Diseases and Nutrition (R21) (NIDDK, NCI, ODS)

    • Release Date: April 10, 2006
    • Application Receipt Date: March 2, 2006
    • Expiration Date: November 15, 2006

    The NIDDK and the Division of Cancer Prevention at the NCI invite applications through the exploratory/developmental (R21) grant mechanism from investigators with research interests in gastroenterology, hepatology, obesity, and nutrition and that serve the mission of NIDDK and NCI. The aim of this funding opportunity is to stimulate the application of highly novel approaches to important areas of digestive diseases (including associated cancers) and nutrition research. Areas of special interest in this funding opportunity include development of novel non invasive imaging methods to study function of the gastrointestinal tract, liver, pancreas and adipose tissue and pathogenic processes such as fibrosis, inflammation, hyperplasia, fat body accumulation.

    See full description in NIH Guide:PA-06-149

  • PAR-06-313: Cancer prevention research small grant program (R03) (NCI)

    • Release Date: April 04, 2006
    • Application Receipt Date: July 20, 2006; November 20, 2006; March 20, 2007; July 21, 2007; December 20, 2007
    • Expiration Date: December 21, 2007
    • Contacts:

      Padma Maruvada, Ph.D. (Early Detection), Phone: 301-496-3893, Email:

    The Division of Cancer Prevention of the NCI invites applications that address developmental research in chemoprevention agent development, biomarkers, early detection, and nutrition science. However, it is important to note that this funding opportunity does not include applications that are focused on treatment, etiology, or treatment-related quality of life studies that are population based. This Small Grants Program is designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of research expertise in cancer prevention research. It is anticipated that this Small Grant Program may lead to the submission of subsequent individual research project grants (R01).

    See full description in NIH Guide:PAR-06-313